You are here: Industry Insights > psoriasis

News List

Johnson & Johnson’s Tremfya tops Novartis blockbuster Cosentyx in head-to-head psoriasis showdown fiercepharma
December 14, 2018
Johnson & Johnson’s Tremfya may have made its debut after key rivals, but it made waves Wednesday in the next-gen psoriasis field with Cosentyx-topping head-to-head data.
Plaque psoriasis study claims Tremfya superior to Cosentyx pharmatimes
December 13, 2018
Janssen’s plaque psoriasis treatment Tremfya was found to be superior to Novartis' Cosentyx in treating adults with moderate-to-severe cases of the condition, according to findings of a late-stage study.
NICE okays UCB’s Cimzia, nixes Almirall’s Ilumetri, in psoriasis pharmaphorum
December 06, 2018
NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but decided that Almirall’s rival Ilumetri does not represent good value for money.
Could treating psoriasis in the future be as easy as going online? worldpharmanews
October 09, 2018
For approximately 8 million Americans, visiting a doctor regularly is the key to managing their psoriasis, a chronic inflammatory skin condition characterized by itchy or painful red patches that can appear anywhere on the body.
AbbVie Announces Patient-Reported Outcomes Data from Risankizumab Studies americanpharmaceuticalreview
September 18, 2018
AbbVie announced new patient-reported outcomes data from three pivotal Phase 3 trials evaluating risankizumab, an investigational interleukin-23 (IL-23) inhibitor...
AbbVie builds case for potential psoriasis blockbuster risankizumab ahead of regulatory decisions fiercebiotech
September 14, 2018
AbbVie’s patient-reported outcomes cement the impression that risankizumab is more effective than Stelara and Humira.
Bristol-Myers Squibb begins phase 3 enrollment after psoriasis drug shows high skin clearance fiercebiotech
September 13, 2018
Two-thirds to three-quarters of patients taking 3 mg twice daily or more showed at least 75% skin clearance after 12 weeks, compared to 7% taking placebo.
GSK sells psoriasis/dermatitis therapy to Dermavant pharmatimes
July 13, 2018
GlaxoSmithKline has sold rights to an experimental therapy with potential in psoriasis and dermatitis to Dermavant in a deal worth $330 million.
EU green light for Cimzia to treat psoriasis pharmatimes
July 04, 2018
The European Medicines Agency has approved a label extension for UCB’s Cimzia allowing its use to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
US approves UCB’s Cimzia for psoriasis pharmatimes
June 06, 2018
US regulators have expanded the reach of UCB’s Cimzia, allowing its use to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page